BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24824988)

  • 1. Delphinidin, one of the major anthocyanidins, prevents bone loss through the inhibition of excessive osteoclastogenesis in osteoporosis model mice.
    Moriwaki S; Suzuki K; Muramatsu M; Nomura A; Inoue F; Into T; Yoshiko Y; Niida S
    PLoS One; 2014; 9(5):e97177. PubMed ID: 24824988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dietary anthocyanin delphinidin prevents bone resorption by inhibiting Rankl-induced differentiation of osteoclasts in a medaka (Oryzias latipes) model of osteoporosis.
    Imangali N; Phan QT; Mahady G; Winkler C
    J Fish Biol; 2021 Apr; 98(4):1018-1030. PubMed ID: 32155282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression.
    Cheon YH; Baek JM; Park SH; Ahn SJ; Lee MS; Oh J; Kim JY
    BMC Complement Altern Med; 2015 Aug; 15():280. PubMed ID: 26271279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice.
    Zhao D; Wang Q; Zhao Y; Zhang H; Sha N; Tang D; Liu S; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B
    Menopause; 2018 Dec; 25(12):1459-1469. PubMed ID: 29944638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-osteoporotic effect of Yijung-tang in an ovariectomized rat model mediated by inhibition of osteoclast differentiation.
    Kim T; Ha H; Shim KS; Cho WK; Ma JY
    J Ethnopharmacol; 2013 Mar; 146(1):83-9. PubMed ID: 23219731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways.
    Hsiao HB; Lin H; Wu JB; Lin WC
    Osteoporos Int; 2013 May; 24(5):1663-76. PubMed ID: 23143538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-Epicatechin 3-O-β-D-allopyranoside prevent ovariectomy-induced bone loss in mice by suppressing RANKL-induced NF-κB and NFATc-1 signaling pathways.
    Hsiao HB; Wu JB; Lin WC
    BMC Complement Altern Med; 2017 May; 17(1):245. PubMed ID: 28468652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice.
    Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W
    J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethanol extract of Polyscias fruticosa leaves suppresses RANKL-mediated osteoclastogenesis in vitro and LPS-induced bone loss in vivo.
    Tran PT; Dang NH; Kim O; Van Cuong P; Dat NT; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Jun; 59():152908. PubMed ID: 30981187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling.
    Kwak SC; Baek JM; Lee CH; Yoon KH; Lee MS; Kim JY
    Int J Biol Sci; 2019; 15(11):2427-2437. PubMed ID: 31595160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
    Jia Y; Jiang J; Lu X; Zhang T; Zhao K; Han W; Yang W; Qian Y
    J Cell Physiol; 2019 May; 234(5):7498-7509. PubMed ID: 30471112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.
    Yamashita T; Yao Z; Li F; Zhang Q; Badell IR; Schwarz EM; Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF
    J Biol Chem; 2007 Jun; 282(25):18245-18253. PubMed ID: 17485464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.